HeimMANKIND • NSE
add
Mankind Pharma Ltd
Við síðustu lokun
2.328,70 ₹
Dagbil
2.275,00 ₹ - 2.351,70 ₹
Árabil
1.901,05 ₹ - 3.054,80 ₹
Markaðsvirði
946,06 ma. INR
Meðalmagn
681,80 þ.
V/H-hlutf.
45,13
A/V-hlutfall
-
Aðalkauphöll
NSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (INR) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 32,30 ma. | 23,90% |
Rekstrarkostnaður | 16,57 ma. | 29,21% |
Nettótekjur | 3,80 ma. | -16,20% |
Hagnaðarhlutfall | 11,77 | -32,40% |
Hagnaður á hvern hlut | 9,44 | -16,53% |
EBITDA | 7,34 ma. | 27,38% |
Virkt skatthlutfall | 22,68% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (INR) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 47,27 ma. | 103,22% |
Heildareignir | — | — |
Heildarskuldir | — | — |
Eigið fé alls | 107,89 ma. | — |
Útistandandi hlutabréf | 402,36 m. | — |
Eiginfjárgengi | 8,83 | — |
Arðsemi eigna | — | — |
Ávöxtun eigin fjár | 14,14% | — |
Peningaflæði
Breyting á handbæru fé
| (INR) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 3,80 ma. | -16,20% |
Handbært fé frá rekstri | — | — |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | — | — |
Frjálst peningaflæði | — | — |
Um
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.
As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
Framkvæmdastjóri
Stofnsett
1991
Vefsvæði
Starfsfólk
19.540
